Bonum Therapeutics
Megan Sprague has extensive work experience in the field of molecular biology and diagnostics. Megan worked as a Scientist at Bonum Therapeutics since February 2023. Prior to that, they were a Scientist II at Just - Evotec Biologics from November 2019 to February 2023. Megan also served as an Associate Scientist at Aptevo Therapeutics Inc from July 2018 to November 2019. Megan's earlier experience includes working as a Scientist at Micronics from an unknown start date to July 2018. At Micronics, they were responsible for the development and optimization of molecular assays and the integration of assays onto the PanNAT system. Megan also played a crucial role in preparing and executing clinical verification and validation studies for the PanNAT platform. Megan has expertise in primer and probe design, plasmid preparation, statistical data analysis, and communication of results to diverse audiences.
Megan Sprague attended the University of Washington from 2007 to 2011, where they earned a Bachelor of Science degree in Biology. In 2009, they also briefly attended Bellevue College, but did not obtain a degree nor specify a field of study during that time.
This person is not in any offices
Bonum Therapeutics
Bonum Therapeutics is creating a technology platform that can be used to treat a wide range of diseases, including cancer which is the company’s primary therapeutic area of focus—as well as metabolic diseases, immunology, and pain management.